165 related articles for article (PubMed ID: 26516158)
1. Tumor-Priming Smoothened Inhibitor Enhances Deposition and Efficacy of Cytotoxic Nanoparticles in a Pancreatic Cancer Model.
Roy Chaudhuri T; Straubinger NL; Pitoniak RF; Hylander BL; Repasky EA; Ma WW; Straubinger RM
Mol Cancer Ther; 2016 Jan; 15(1):84-93. PubMed ID: 26516158
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of tumor vascular priming by a nanoparticulate doxorubicin formulation.
Roy Chaudhuri T; Arnold RD; Yang J; Turowski SG; Qu Y; Spernyak JA; Mazurchuk R; Mager DE; Straubinger RM
Pharm Res; 2012 Dec; 29(12):3312-24. PubMed ID: 22798260
[TBL] [Abstract][Full Text] [Related]
3. Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model.
Wang J; Chan DKW; Sen A; Ma WW; Straubinger RM
Mol Cancer Ther; 2019 Nov; 18(11):2074-2084. PubMed ID: 31363010
[TBL] [Abstract][Full Text] [Related]
4. Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model.
Arnold RD; Mager DE; Slack JE; Straubinger RM
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8856-65. PubMed ID: 16361575
[TBL] [Abstract][Full Text] [Related]
5. Systems pharmacological analysis of paclitaxel-mediated tumor priming that enhances nanocarrier deposition and efficacy.
Ait-Oudhia S; Straubinger RM; Mager DE
J Pharmacol Exp Ther; 2013 Jan; 344(1):103-12. PubMed ID: 23115220
[TBL] [Abstract][Full Text] [Related]
6. [Cellular toxicity and anti-tumor efficacy of iRGD modified doxorubixin loaded sterically stabilized liposomes].
Zhao B; Fan YC; Wang XQ; Dai WB; Zhang Q; Wang XL
Yao Xue Xue Bao; 2013 Mar; 48(3):417-22. PubMed ID: 23724658
[TBL] [Abstract][Full Text] [Related]
7. Integrated PK/PD Modeling Relates Smoothened Inhibitor Biomarkers to The Heterogeneous Intratumor Disposition of Cetuximab in Pancreatic Cancer Tumor Models.
Wang J; Chen T; Ruszaj DM; Mager DE; Straubinger RM
J Pharm Sci; 2024 Jan; 113(1):72-84. PubMed ID: 37844759
[TBL] [Abstract][Full Text] [Related]
8. Synergistic antitumor activity of metronomic dosing of cyclophosphamide in combination with doxorubicin-containing PEGylated liposomes in a murine solid tumor model.
Ishida T; Shiraga E; Kiwada H
J Control Release; 2009 Mar; 134(3):194-200. PubMed ID: 19095022
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of liposomal chemophototherapy with short drug-light intervals.
Luo D; Carter KA; Molins EAG; Straubinger NL; Geng J; Shao S; Jusko WJ; Straubinger RM; Lovell JF
J Control Release; 2019 Mar; 297():39-47. PubMed ID: 30684512
[TBL] [Abstract][Full Text] [Related]
10. The modulation of tumor vessel permeability by thalidomide and its impacts on different types of targeted drug delivery systems in a sarcoma mouse model.
Wang D; Fu J; Shi Y; Peng D; Yuan L; He B; Dai W; Zhang H; Wang X; Tian J; Zhang Q
J Control Release; 2016 Sep; 238():186-196. PubMed ID: 27422610
[TBL] [Abstract][Full Text] [Related]
11. Comprehensively priming the tumor microenvironment by cancer-associated fibroblast-targeted liposomes for combined therapy with cancer cell-targeted chemotherapeutic drug delivery system.
Chen B; Dai W; Mei D; Liu T; Li S; He B; He B; Yuan L; Zhang H; Wang X; Zhang Q
J Control Release; 2016 Nov; 241():68-80. PubMed ID: 27641831
[TBL] [Abstract][Full Text] [Related]
12. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.
Pastorino F; Brignole C; Di Paolo D; Nico B; Pezzolo A; Marimpietri D; Pagnan G; Piccardi F; Cilli M; Longhi R; Ribatti D; Corti A; Allen TM; Ponzoni M
Cancer Res; 2006 Oct; 66(20):10073-82. PubMed ID: 17047071
[TBL] [Abstract][Full Text] [Related]
13. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
[TBL] [Abstract][Full Text] [Related]
14. Hedgehog inhibition with the orally bioavailable Smo antagonist LDE225 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms.
Fendrich V; Wiese D; Waldmann J; Lauth M; Heverhagen AE; Rehm J; Bartsch DK
Ann Surg; 2011 Nov; 254(5):818-23; discussion 823. PubMed ID: 22042473
[TBL] [Abstract][Full Text] [Related]
15. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
Shiraga E; Barichello JM; Ishida T; Kiwada H
Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
[TBL] [Abstract][Full Text] [Related]
16. Phospho-valproic acid inhibits pancreatic cancer growth in mice: enhanced efficacy by its formulation in poly-(L)-lactic acid-poly(ethylene glycol) nanoparticles.
Mattheolabakis G; Wang R; Rigas B; Mackenzie GG
Int J Oncol; 2017 Oct; 51(4):1035-1044. PubMed ID: 28849098
[TBL] [Abstract][Full Text] [Related]
17. Sonic-hedgehog pathway inhibition normalizes desmoplastic tumor microenvironment to improve chemo- and nanotherapy.
Mpekris F; Papageorgis P; Polydorou C; Voutouri C; Kalli M; Pirentis AP; Stylianopoulos T
J Control Release; 2017 Sep; 261():105-112. PubMed ID: 28662901
[TBL] [Abstract][Full Text] [Related]
18. Effect of ligand density and PEG modification on octreotide-targeted liposome via somatostatin receptor in vitro and in vivo.
Li H; Yuan D; Sun M; Ping Q
Drug Deliv; 2016 Nov; 23(9):3562-3572. PubMed ID: 27432585
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT
Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479
[TBL] [Abstract][Full Text] [Related]
20. Dual-Hit Strategy for Therapeutic Targeting of Pancreatic Cancer in Patient-Derived Xenograft Tumors.
Roy Chaudhuri T; Lin Q; Stachowiak EK; Rosario SR; Spernyak JA; Ma WW; Stachowiak MK; Greene MK; Quinn GP; McDade SS; Clynes M; Scott CJ; Straubinger RM
Clin Cancer Res; 2024 Apr; 30(7):1367-1381. PubMed ID: 38270582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
